Navigation Links
YM BioSciences third quarter 2010 operational and financial results

MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today reported operational and financial results for the third quarter of fiscal 2010, ended March 31, 2010.

"During the third quarter, we completed the merging into YM of Cytopia Limited, now YM BioSciences Australia, expanding our pipeline through the addition of two promising new drug candidates in drug classes that have been established as being of high interest and value to the pharmaceutical industry," said David Allan, Chairman and CEO of YM BioSciences. "With a strengthened balance sheet from our recent financing and a portfolio of four late-stage products, the quality and prospects for our drug portfolio are unmatched in YM's history as a company. This quarter we gathered momentum in for our clinical programs with an expansion of our Phase I/II clinical trial for CYT387 as well as the acceptance and presentation of our data at several international forums. We look forward to numerous clinical and corporate events during the balance of 2010."

Highlights for the third quarter of Fiscal 2010:

    -   Merged Cytopia (now YM BioSciences Australia), a clinical-stage, drug
        development company based in Melbourne, Australia, into YM.

    -   Cleared by the US FDA to enroll patients at US clinical sites into
        two ongoing randomized, double-blind Phase II trials of our lead
        product, nimotuzumab.

    -   Expanded the current Phase I/II clinical trial in myelofibrosis
        through an earlier-than-planned initiation of the Phase II component
        of the study for CYT387, the company's highly selective and potent
        JAK1/2 inhibitor.

    -   Had two posters accepted for presentation at the American Association
        for Cancer Research (AACR) Annual Meeting held on April 17-21 in
        Washington, DC.

    -   Presented posters on CYT387 and CYT997, the Company's novel vascular
        disrupting agent, at the Lorne Cancer Conference in Lorne, Victoria,

    -   Published pivotal preclinical data for CYT387 as a First Edition in
        the premier hematology journal Blood.

    -   Had granted two additional patents in the US for AeroLEF(R), our
        proprietary, inhaled-delivery composition of free and liposome-
        encapsulated fentanyl for the treatment of moderate to severe acute

    -   Reported positive results on the selective activity of a highly
        potent antibody-radionuclide with nimotuzumab in breast cancer cells
        resulting from a collaboration with researchers at the University of

    -   Appointed Rogerio C. Lilenbaum, M.D., M. Sc., Minesh Mehta, M.D., and
        Roman Perez-Soler, M.D., together with two additional leading US
        oncologists have to a US Consultative Committee to YM on the ongoing
        development YM's anti-cancer products.

    -   Closed registered direct offering for gross proceeds of approximately
        US $17.5 million.

Subsequent to the quarter end, the Company initiated an "At-The-Market" financing facility for up to 7.5 million common shares.

"The substantial liquidity in our share trading permits us to access this innovative financing mechanism which will provide us with important flexibility in the timing of any future financing and, if implemented, should significantly reduce our overall cost of capital," said Mr. Allan. "This established mechanism has been used across multiple industries by numerous companies including several life-sciences companies and is designed to result in the issuance of shares at no discount to the quoted market at the time of a transaction. We are not required to sell any shares at any time during the term of the offering, which extends until October 16, 2011; there are no stand-by fees for the arrangement and we are not prohibited from conducting other forms of financing should such be required for further expansion or for the conduct of our business."

Financial Results (CDN dollars)

Total revenue (out-licensing revenue and interest income) for the third quarter of fiscal 2010, ended March 31, 2010 was $709 thousand compared with $1.0 million for the third quarter of fiscal 2009. Total revenue for the first nine months of fiscal 2010 was $2.2 million compared with $4.8 million for the first nine months of fiscal 2009. The decrease in both periods was due mainly to the extension of the recognition periods for the initial payments for the Daiichi Pharmaceutical Co., Ltd. and Kuhnil Pharmaceuticals Co., Ltd. contracts by 12 months effective January 1, 2009 and no revenue in 2009 from the Innogene Kalbiotech Private Limited contract which was fully recognized at December 2008. Offsetting this decrease was the recognition of the remaining deferred revenue for the tesmilifene contracts, totaling $228 thousand. This revenue has been fully recognized in this period because we are no longer developing tesmilifene and these contracts are no longer active.

General and administrative expenses were $1.6 million for the third quarter of fiscal 2010 compared with $1.2 million for the third quarter of fiscal 2009. General and administrative expenses were $5.1 million for the first nine months of fiscal 2010 compared with $3.5 million for the first nine months of fiscal 2009. The increase for the three and nine months ended March 31, 2010 over the comparative periods was due mainly to legal, consulting and investor relations fees related to the acquisition of Cytopia Limited.

Licensing and product development expenses were $4.5 million for the third quarter of fiscal 2010 compared with $3.3 million for the third quarter of fiscal 2009. Licensing and product development expenses were $9.3 million for the first nine months of fiscal 2010 compared with $11.5 million for the first nine months of fiscal 2009. The increase in the current quarter is mainly attributable to the addition of the Australian office, resulting in increased office, travel and salary expenditures.

Costs associated with development activities for nimotuzumab increased by $309 thousand to $1.8 million and decreased by $921 thousand to $3.8 million for the three and nine months ended March 31, 2010, respectively, compared to the same periods in the prior year. The current year's costs were due mainly to the two new clinical trials for non-small cell lung cancer patients ineligible for radical chemotherapy (NSCLC) and brain metastases from non-small cell lung cancer, the ongoing glioma trial, and the new BRI project.

Costs associated with development activities for AeroLEFÒ decreased by $304 thousand to $109 thousand and by $1.1 million to $418 thousand for the three and nine months ended March 31, 2010, respectively, compared the same periods in the prior year. Costs in the current year were due mainly to out-licensing initiatives, analytical development, stability studies and IP management.

Net loss for the third quarter of fiscal 2010 was $5.5 million ($0.09 per share) compared to $3.5 million ($0.06 per share) for the same period last year. Net loss for the first nine months of fiscal 2010 was $12.4 million ($0.21 per share) compared to $9.8 million ($0.18 per share) for the same period last year.

As at March 31, 2010 the Company had cash and short-term deposits totalling $48 million and accounts payables and accrued liabilities totalling $3.2 million compared to $42.1 million and $918 thousand respectively, at June 30, 2009.

As at March 31, 2010 the Company had 77,849,623 common shares outstanding, of which 2,380,953 common shares are held in escrow to be released contingent upon the completion of certain milestones.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company. Together with the products from YM BioSciences Australia, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a JAK 1/2 small molecule inhibitor; CYT997, a potent, vascular disrupting agent (VDA); and AeroLEFÒ, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The clinical stage products discovered by Cytopia Ltd (YM Australia since January 2010) include the JAK 1/2 inhibitor, CYT387, and the novel VDA molecule, CYT997. Both were developed internally at Cytopia from research led by Dr. Andrew Wilks who discovered and named the Janus kinases. Cytopia's earlier stage portfolio includes a JAK3 program that was the subject of a research collaboration underwritten by Novartis that concluded in 2009 with any further development residing exclusively with Novartis; an ongoing collaborative research project with the Melbourne-based Cooperative Research Centre for Cancer Therapeutics (CRC CTx) for the development of Cytopia's inhibitors of Focal Adhesion Kinase (FAK), a protein implicated in progression and metastasis of numerous solid tumors; and a novel series of compounds that inhibit the kinase FMS which have been demonstrated to have excellent potency and selectivity. Approximately 4,000 additional novel compounds have been amassed from Cytopia's own research and are being reviewed. YM's other discovery programs include the IntellimabÒ platform of uniquely optimized antibodies designed to selectively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars, unless otherwise indicated)

                                                    March 31,        June 30,
                                                        2010            2009

    Current assets:
      Cash                                      $  27,862,417  $   2,337,716
      Short-term deposits                          20,149,367     39,713,042
      Accounts receivable                             390,714        564,584
      Prepaid expenses                                129,589        352,850
                                                   48,532,087     42,968,192

    Property and equipment                             95,794         96,876

    Intangible assets                              14,982,168      3,004,868

                                                $  63,610,049  $  46,069,936

    Liabilities and Shareholders' Equity

    Current liabilities:
      Accounts payable                          $   1,084,901  $     431,028
      Accrued liabilities                           2,142,707        486,723
      Deferred revenue                              1,527,596      2,549,568
                                                    4,755,204      3,467,319

    Deferred revenue                                2,031,888      2,898,292

    Shareholders' equity:
      Share capital                               200,168,284    172,921,153
      Share purchase warrants                       1,473,246              -
      Contributed surplus                          13,802,582     13,035,123
      Deficit                                    (158,621,155)  (146,251,951)
                                                   56,822,957     39,704,325

    Basis of presentation
    Subsequent event

                                                $  63,610,049  $  46,069,936

    Interim Consolidated Statements of Operations, Comprehensive
    Income and Deficit
    (Expressed in Canadian dollars, unless otherwise indicated)

                        Three months ended            Nine months ended
                             March 31,                     March 31,
                           2010           2009           2010           2009
                            (Unaudited)                   (Unaudited)

     revenue      $     690,585  $     776,127  $   2,115,706  $   3,823,296
     income              18,901        201,635         51,194      1,009,323
                        709,486        977,762      2,166,900      4,832,619

       and product
       development    4,526,244      3,259,177      9,335,238     11,525,789
      General and
       administrative 1,623,900      1,190,039      5,107,662      3,530,626
                      6,150,144      4,449,216     14,442,900     15,056,415

    Loss before
     the undernoted  (5,440,658)    (3,471,454)   (12,276,000)   (10,223,796)

    Gain (loss)
     on foreign
     exchange           (39,418)        51,122        (73,295)       143,009
    Loss on
     deposits           (10,803)       (54,507)       (19,909)       (31,789)
    Other income              -              -              -        307,140

    Loss and
     loss for the
     period          (5,490,879)    (3,474,839)   (12,369,204)    (9,805,436)

     beginning of
     period        (153,130,276)  (139,513,082)  (146,251,951)  (133,182,485)

    Deficit, end
     of period    $(158,621,155) $(142,987,921) $(158,621,155) $(142,987,921)

    Basic and
     diluted loss
     per common
     share        $       (0.09) $       (0.06) $       (0.21) $       (0.18)


     number of
     outstanding     64,286,027     55,835,356     58,639,741     55,835,356

     common shares
     held in
     escrow for
     related to
     the acquisition
     of Delex
     Inc.             2,380,953      2,380,953      2,380,953      2,380,953


    Interim Consolidated Statements of Cash Flows
    (Expressed in Canadian dollars, unless otherwise indicated)

                        Three months ended            Nine months ended
                             March 31,                     March 31,
                           2010           2009           2010           2009
                            (Unaudited)                   (Unaudited)

    Cash provided
     by (used in):

      Loss for
       the period $  (5,490,879) $  (3,474,839) $ (12,369,204) $  (9,805,436)
      Items not
         tion of
         equipment       14,708         19,806         48,291         57,282
         tion of
         assets       1,016,482        265,135      1,546,753        795,406
        Loss on
         deposits        10,803         56,219         19,909         33,501
         compensation   179,394        195,023        694,084        574,579
      Change in
         expenses       250,722        255,258        584,317        (45,639)
         ties and
         revenue       (840,332)      (767,508)    (1,568,007)    (3,036,153)
                     (4,859,102)    (3,450,906)   (11,043,857)   (11,426,460)

      Issuance of
       shares on
       exercise of
       options           21,550              -         84,139              -
      Net proceeds
       from issuance
       of shares and
       warrants      16,067,710              -     16,067,710              -
                     16,089,260              -     16,151,849              -

       net          (14,986,525)     4,233,479      9,543,766     17,259,293
      Additions to
       property and
       equipment        (19,099)       (19,114)       (36,636)       (34,150)
                    (15,005,624)     4,214,365     19,507,130     17,225,143

     (decrease) in
     cash            (3,775,466)       763,459     24,615,122      5,798,683

    Net cash
     assumed on
     acquisition        909,579              -        909,579              -

    Cash, beginning
     of period       30,728,304      8,154,413      2,337,716      3,119,189

    Cash, end of
     period       $  27,862,417  $   8,917,872  $  27,862,417  $   8,917,872

     of non-cash
      Issuance of
       shares on
       of Cytopia
       Limited    $  12,515,903  $           -  $  12,515,903  $           -
      Issuance of
       options on
       of Cytopia
       Limited          126,000              -        126,000              -
      Issuance of
       warrants         175,371              -        175,371              -


SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a ... Market for Liquid Biopsy is growing rapidly and expected to reach ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a swiftly ... figures and boom in the coming future. There has been a ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... Md. and GAITHERSBURG, Md. ... (NYSE MKT: PIP) and Altimmune, Inc., a privately-held ... signing of a definitive agreement for the merger ... Altimmune,s current investors include Novartis Venture Fund, HealthCap, ... will be a fully-integrated and diversified immunotherapeutics company ...
(Date:1/19/2017)... ... 18, 2017 , ... The American Medical Informatics Association (AMIA) ... Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should ... AMIA recommended that NIH earmark funding for researchers to produce and execute data ...
Breaking Biology Technology:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):